LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that the first patient has been enrolled in a Phase I trial of the Company’s drug candidate CB3304 (noscapine), an orally active inhibitor of microtubule dynamics. The Phase I trial of CB3304 is an open label, dose escalating study to evaluate the safety and efficacy of CB3304 administered daily to patients with relapsed or refractory multiple myeloma. The trial will be conducted at Weill Cornell Medical College and Columbia Presbyterian Medical Center.
